Obstructive sleep apnea hypopnea syndrome
Conditions
Interventions
Experimental group:Intravenous remimazolam tosilate (0.2 mg/kg) before examination
Sponsors
Xiangya Hospital of Central South University
Eligibility
Sex/Gender
All
Age
18 Years to 60 Years
Inclusion criteria
Inclusion criteria: 1. Patients diagnosed with obstructive sleep apnea hypopnea syndrome before surgery and planning to undergo drug-induced sleep endoscopy; 2. Aged 18 to 60 years; 3. ASA is graded I-III.
Exclusion criteria
Exclusion criteria: 1. Those who intend to receive endotracheal intubation or implantation of a laryngeal mask; 2. Patients who have recently used sedatives or analgesics; 3. Those who are allergic or contraindicated to benzodiazepines, opioids, propofol and their components; 4. Patients with severe respiratory and circulatory insufficiency; 5. People with mental illness, long-term use of psychotropic drugs and cognitive impairment; 6. Patients with severe immune insufficiency (such as AIDS, etc.); 7. Patients with severe hepatic and renal insufficiency; 8. Pregnant or lactating patients; 9. Those who have participated in other clinical trials within the last 3 months.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Sedation success rate;Heart rate;non-invasive blood pressure; | — |
Countries
China
Contacts
Public ContactHuang Changsheng
Xiangya Hospital of Central South University
Outcome results
None listed